Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

6
205
1
7

Year Published

2018
2018
2024
2024

Publication Types

Select...
4
3
2
1

Relationship

2
8

Authors

Journals

citations
Cited by 218 publications
(219 citation statements)
references
References 28 publications
6
205
1
7
Order By: Relevance
“…i) The DNDi-CH-E1224-001 clinical trial (NCT01489228), designed and sponsored by DND i , a proof-of-concept double-blinded randomized trial aiming to evaluate the safety and efficacy of three (high, low, and short) oral regimens of E1224, compared to BZN (5 mg/kg/day) and placebo, during 60 days of treatment of adult patients with chronic indeterminate Chagas disease [14].…”
Section: Methodsmentioning
confidence: 99%
“…i) The DNDi-CH-E1224-001 clinical trial (NCT01489228), designed and sponsored by DND i , a proof-of-concept double-blinded randomized trial aiming to evaluate the safety and efficacy of three (high, low, and short) oral regimens of E1224, compared to BZN (5 mg/kg/day) and placebo, during 60 days of treatment of adult patients with chronic indeterminate Chagas disease [14].…”
Section: Methodsmentioning
confidence: 99%
“…Chemical structures of the new generation of azoles VNI and VFV, and old azoles ravuconazole and posaconazole that inhibit the T. cruzi sterol 14 αdemethylase. VNI [20] and VFV [21] are new promising drug candidates in pre-clinical studies, whereas ravuconazole and posaconazole entered unsuccessful clinical trials [139,11].…”
Section: Squalene Synthase (Sqs)mentioning
confidence: 99%
“…Therefore, E1224 ( Figure 4D) was developed as a prodrug of ravuconazole. A phase II Clinical Trial was performed in 2013 to evaluate the prodrug efficacy and safety compared to BNZ, as a randomized double-blinded placebocontrolled proof-of-concept study [115]. The study was performed in 224 patients with chronic indeterminate CD.…”
Section: Clinical Trialsmentioning
confidence: 99%